
RETATRUTIDE
Triple-receptor metabolic technology targeting GLP-1, GIP & glucagon pathways.
Compounds built around metabolic, incretin and appetite pathways.

A dual GIP and GLP-1 receptor agonist designed around two major incretin pathways involved in appetite, glucose regulation, and metabolic function.

A growth hormone-releasing hormone analog that activates the body's GH signaling pathway and influences downstream IGF-1 activity.